U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Li
Molecular Weight 6.94
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of LITHIUM CATION

SMILES

[Li+]

InChI

InChIKey=HBBGRARXTFLTSG-UHFFFAOYSA-N
InChI=1S/Li/q+1

HIDE SMILES / InChI

Molecular Formula Li
Molecular Weight 6.94
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19538681 | https://www.ncbi.nlm.nih.gov/pubmed/23371914 | http://www.rsc.org/periodic-table/element/3/lithium

Lithium gluconate is used in oligotherapy for psychological problems (normothymia, manic depressive psychosis) under special biological surveillance and more specifically when the lithium rate is to be controlled. Lithium gluconate ointment was significantly more effective than placebo, with a complete clinical remission after 4 and 8 weeks respectively in the treatment of seborrhoeic dermatitis. At low concentration (1.6 mM), Li enhanced TNFalpha secretion, whereas, at higher concentration (5 mM), Li significantly enhanced IL10 expression and secretion in skin models. However, there was no significant modulation of Li on IL6 and TGFbeta1 secretion. Moreover, Li at 5 mM significantly decreased TLR2 and TLR4 expressions by differentiated keratinocytes. As Li concentration during topical treatment is probably closer to 5 mM than to 1 mM, the therapeutic effect of Li gluconate in seborrhoeic dermatitis may be explained by two anti-inflammatory actions: an increased expression and secretion of IL10 and a decreased expression of TLR2 and TLR4 by keratinocytes.

Originator

Curator's Comment:: The first lithium mineral petalite, LiAlSi4O10, was discovered on the Swedish island of Utö by the Brazilian, Jozé Bonifácio de Andralda e Silva in the 1790s. It was observed to give an intense crimson flame when thrown onto a fire. In 1817, Johan August Arfvedson of Stockholm analysed it and deduced it contained a previously unknown metal, which he called lithium. He realised this was a new alkali metal and a lighter version of sodium. However, unlike sodium he was not able to separate it by electrolysis. In 1821 William Brande obtained a tiny amount this way but not enough on which to make measurements. It was not until 1855 that the German chemist Robert Bunsen and the British chemist Augustus Matthiessen obtained it in bulk by the electrolysis of molten lithium chloride.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.53 µM [IC50]
2.0 mM [Ki]
Target ID: O95861
Gene ID: 10380.0
Gene Symbol: BPNT1
Target Organism: Homo sapiens (Human)
0.3 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LITHIUM CARBONATE

Approved Use

Lithium is indicated in the treatment of manic episodes of Bipolar Disorder.

Launch Date

-1.26316798E11
PubMed

PubMed

TitleDatePubMed
[Lithium therapy in manic depressive diseases in old age].
1975
[Lithium induced diabetes insipidus with response to antidiuretic hormone].
1975 Apr 28
Lithium induced nephrogenic diabetes insipidus: changes in plasma vasopressin and angiotensin II.
1975 Jun
[Side-effects of lithium therapy].
1975 Mar
[Treatment of lithium induced polyuria].
1975 Mar 10
Organophosphate poisoning: modifications in acid base equilibrium and use of sodium bicarbonate as an aid in the treatment of toxicity in dogs.
1983 Feb
Bupivacaine cardiotoxicity in a pregnant patient with mitral valve prolapse.
1983 Jun
Experimental amitriptyline intoxication: electrophysiologic manifestations and management.
1984 Jan-Feb
Experimental amitriptyline intoxication: treatment of cardiac toxicity with sodium bicarbonate.
1986 Sep
Summation effects of uracil and other promoters on epithelial lesion development in the F344 rat urinary bladder initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine.
1991 Nov
Reversal of desipramine toxicity in rats using drug-specific antibody Fab' fragment: effects on hypotension and interaction with sodium bicarbonate.
1992 Mar
Effects of magnesium sulfate and lidocaine in the treatment of ventricular arrhythmias in experimental amitriptyline poisoning in the rat.
1994 Mar
Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate in dogs.
1995 May
Neutralizing pH of lidocaine reduces pain during Norplant system insertion procedure.
1995 May
Reduction of desipramine cardiotoxicity and prolongation of survival in rats with the use of polyclonal drug-specific antibody Fab fragments.
1995 Sep
Therapy of Sjögren's syndrome. New aspects and future directions.
1998 Feb
Sodium bicarbonate treatment reduces renal injury, renal production of transforming growth factor-beta, and urinary transforming growth factor-beta excretion in rats with doxorubicin-induced nephropathy.
1999 Aug
[Severe flecainide acetate poisoning. Apropos of a case].
1999 Feb
Seizure-induced neuronal necrosis: implications for programmed cell death mechanisms.
2000
Olanzapine-induced urinary incontinence: treatment with ephedrine.
2000 Aug
Regulation of AQP6 mRNA and protein expression in rats in response to altered acid-base or water balance.
2000 Dec
Influence of chronic barbiturate administration on sleep apnea after hypersomnia presentation: case study.
2000 Sep
Antidepressant-induced mania in bipolar patients: identification of risk factors.
2001 Apr
Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline.
2001 Apr
Ménière's disease in childhood.
2001 Dec 1
Lithium inhibits cell cycle progression and induces stabilization of p53 in bovine aortic endothelial cells.
2001 Jul 13
Lithium-induced exacerbation of stutter.
2001 Jul-Aug
Molecular cloning of a novel isoform of diphosphoinositol polyphosphate phosphohydrolase: a potential target of lithium therapy.
2001 Jun
Lithium-induced nephrogenic diabetes insipidus.
2001 Mar
Renal tubular peptide catabolism in chronic vascular rejection.
2001 May-Jul
Aborted sudden death, transient Brugada pattern, and wide QRS dysrrhythmias after massive cocaine ingestion.
2001 Oct
[Lithium treatment and hyperparathyroidism].
2001 Sep 20
Sinus node dysfunction associated with lithium therapy in a child.
2002
Calcium channel blocker, nimodipine, for the treatment of bipolar disorder during pregnancy.
2002 Dec
Aminophylline aggravates long-term morphological and cognitive damages in status epilepticus in immature rats.
2002 Mar 22
Lithium induces NF-kappa B activation and interleukin-8 production in human intestinal epithelial cells.
2002 Mar 8
Sexual side effects associated with valproate.
2002 Oct
Left-sided splenorenal fusion with marked extramedullary hematopoiesis and concurrent lithium toxicity. A case report and review of the literature.
2003 Jan
The prevention of pain from injection of rocuronium by magnesium sulphate, lignocaine, sodium bicarbonate and alfentanil.
2003 Jun
Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells.
2003 Mar 15
Fanconi syndrome caused by antiepileptic therapy with valproic Acid.
2004 Jul
Contrast medium-induced nephropathy: strategies for prevention.
2008 Sep
G418-mediated ribosomal read-through of a nonsense mutation causing autosomal recessive proximal renal tubular acidosis.
2008 Sep
Sodium bicarbonate versus normal saline for protection against contrast nephropathy.
2009
Mass casualties from acute inhalation of chlorine gas.
2009 Dec
Iatrogenic Flecainide toxicity.
2010 Dec
Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy.
2010 Jan 15
Acute propafenone toxicity after two exposures at standard dosing.
2010 Jun-Jul
Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
2010 Nov
Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity.
2013 Jun
Patents

Sample Use Guides

Optimal patient response to Lithium Carbonate usually can be established and maintained with 600 mg t.i.d. Optimal patient response to Lithium Oral Solution usually can be established and maintained with 10 mL (2 full teaspoons) (16 mEq of lithium) t.i.d. Such doses will normally produce an effective serum lithium level ranging between 1.0 and 1.5 mEq/l. Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient’s clinical state and of serum lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.
Route of Administration: Oral
Although lithium at a high concentration (10 mM) activated β-catenin in different types of neurons, β-catenin shifted to the nucleus at a therapeutically relevant concentration (1 mM) only in thalamic neurons, both in vivo and in vitro.
Substance Class Chemical
Created
by admin
on Sat Jun 26 12:13:08 UTC 2021
Edited
by admin
on Sat Jun 26 12:13:08 UTC 2021
Record UNII
8H8Z5UER66
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LITHIUM CATION
Common Name English
LITHIUM, ION (LI1+)
Common Name English
LITHIUM ION
Common Name English
Classification Tree Code System Code
WHO-ATC N05AN01
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
NCI_THESAURUS C597
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
NDF-RT N0000175751
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
DSLD 499 (Number of products:145)
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
Code System Code Type Description
EPA CompTox
17341-24-1
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
PRIMARY
RXCUI
1546265
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C69075
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
PRIMARY
FDA UNII
8H8Z5UER66
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
PRIMARY
IUPHAR
5212
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
PRIMARY
PUBCHEM
28486
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
PRIMARY
CAS
17341-24-1
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
PRIMARY
DRUG BANK
DB01356
Created by admin on Sat Jun 26 12:13:12 UTC 2021 , Edited by admin on Sat Jun 26 12:13:12 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY